Bruker与ANPC合作，以支持与COVID-19威胁作斗争的主要新一线响应

布鲁克（Bruker）为与默多克大学（Murdoch University）的澳大利亚国家现象中心（ANPC）合作而感到自豪，以支持其研究人员对COVID-19-19大流行威胁的工作。

The ANPC team, led by world-renowned phenomics pioneer and academician Professor Jeremy Nicholson, and working with the South Metropolitan Health Service COVID-19 Response Team and the broader Western Australian (WA) healthcare community, has launched a major research and diagnostics project to better understand and predict variation in COVID-19 severity and determine the complex genetic, environmental and lifestyle interactions that influence its pathogenicity in individuals. Later they will engage with clinical trials of novel antiviral agents and when available vaccines in order to predict responder/non-responder outcomes.

加速诊断时间

The goal is to deliver diagnostic and prognostic solutions in an accelerated time-frame. Most importantly, the risk of severity of infected patients needs to be assessed rapidly to help guide and optimize the clinical patient pathway. Researchers at the ANPC will use a range of state-of-the-artAvance IVDR核磁共振（NMR）和timstof Pro，Impact II和Solarix MR质谱法（MS）Bruker的仪器以及数据建模方法，对血浆和尿液样本的分子，物理和生化特征进行广泛而深层的代谢分析，以创建信息转化模型。这些模型将预测疾病严重程度的差异，并有助于了解治疗干预措施的差异反应。

尼科尔森教授说：“在ANPC，我们将100％的资源献给了Covid-19至少一年。这是地球上最伟大的新兴医疗挑战，在澳大利亚或世界上可能没有更好的代谢实验室，可以在出色的临床和医院框架中从事此类调查工作。

“Linked to our genomics team, led by Professor Simon Mallal and Associate Professor Mark Watson, we’re setting out to identify specific biomarkers of the disease to figure out who has it, how we can detect it and stratify patients by severity risk, and assess the real time patient responses to treatments.”:

科学伙伴关系来推动临床研究

布鲁克公司（Bruker Corporation）总裁兼首席执行官弗兰克·H·劳基恩（Frank H.默多克大学综合的COVID-19临床研究计划涉及疾病，预后和治疗反应的代谢生物标志物模式。

“In particular, I hope that the team can find evidence-based clinical protocols very soon to reduce mortality in ‘phase 2’ of COVID-19 with its life-threatening lower respiratory tract infections. Medical science needs to determine urgently whether broad spectrum antibiotics and/or immunosuppressants improve survival statistics in ‘phase 2’, when viral pneumonia, potential bacterial pneumonia or ventilator-associated pneumonia (VAP), as well as lung inflammation due to our own immune systems’ cytokine storms, appear to create a very dangerous set of co-morbidities.”

独特的生物样品收集能力

该项目将与ANPC与默多克大学和巴黎圣母院的梅里利·尼德姆（Merrilee Needham）和西澳大利亚大学的托比·理查兹（Toby Richards）教授携手合作，他们将来自西澳的顶级医生和研究人员一起到西澳大利亚州。由Gary Geelhood教授为COVID-19响应团队领导的健康翻译网络（WAHTN）。

It is anticipated that all new COVID-19 patients will be consented for testing on admission and later for clinical trials, with the ANPC running the samples from those trials and tests, including longitudinal urine and plasma metabolic monitoring.

Commenting on the unique position of the WA-based research team, Professor Richards said: “We are in the second wave and have the opportunity to be prepared for COVID-19. We have built a unique platform in WA to collect patient data and bio samples to enable a thorough understanding of the disease and response to treatment.”

减轻当前和未来威胁

了解感染途径和生物学后果将使有效的治疗和疫苗能够减轻当前对全球成千上万人的威胁。这项开创性的工作还将为我们准备将来的病毒大流行威胁。

The Australian National Phenome Centre (ANPC), led by Murdoch University, will transform how long and how well people live, not just in Australia, but around the world. The work of the ANPC supports almost every area of bioscience. It reaches across traditional research silos and fosters a new, more collaborative approach to science. Long-term, the ANPC hopes to build ‘global atlases’ of human disease, providing insights into future health risks which everyone on the planet can benefit from. The only facility of its kind in the southern hemisphere, the ANPC brings together all five Western Australian universities and leading health and medical research institutes. It is linked to the International Phenome Centre Network and also has wide applications in agriculture and environmental science. The ANPC positions Perth and WA as a global leader in precision medicine, and enables quantum leaps in predicting, diagnosing and treating disease. It is part of the Health Futures Institute at Murdoch University.

Technology and partners

The ANPC is equipped with multiple state-of-the-art nuclear magnetic resonance (NMR) and mass spectrometry (MS) instruments from ANPC strategic alliance partners Bruker BioSpin and Bruker Daltonics. Bruker is a manufacturer of scientific instruments for molecular and materials research, as well as for industrial and applied analysis.

现象

一个人的现象是其独特生物学的动态指纹，这是由于环境和遗传因素之间的复杂相互作用而产生的。现象学是对环境和一个人的生活方式如何与基因相互作用以影响其健康和疾病风险的研究。代谢表型是对生物组织和液体的分析，以发现分子水平上遗传，环境和生活方式因素的特定相互作用。

Professor Jeremy Nicholson

尼科尔森教授以国际著名的代谢表型和系统医学先驱领导ANPC。他目前担任默多克大学健康期货研究所的职业副校长任命。尼科尔森教授是一位引用高度引用的学者，他发表了有关人体系统医学分子方面的800多个同行评审论文。尼科尔森教授是英国医学科学院的院士，从伦敦帝国学院来到西澳，在那里他是MRC-NIHR国家现象中心的创始董事，也是先前的外科和癌症主管。他目前是伦敦帝国学院的名誉生物化学教授。

伊莱恩·福尔摩斯教授

福尔摩斯教授是另一位系统医学先驱，是一位引用的学者，也是英国医学科学院的会员。福尔摩斯教授还来到伦敦帝国学院的西澳州，她以前曾是计算和系统部门的负责人。她是默多克大学澳大利亚国家现象中心的计算医学教授，也是澳大利亚国家现象中心，她还在伦敦帝国学院担任化学生物学教授。

Dr Ruey-Leng Loo

Premier’s Intermediate Fellow, Senior Lecturer, ANPC, Murdoch University.

托比·理查兹教授

迈克尔·劳伦斯·布朗（Michael Lawrence Brown）外科UWA主席，名誉教授学院伦敦大学学院学院，导演Covid Research Response。

梅里利·尼德姆（Merrilee Needham）教授

Senior Consultant, Director of Research, Fiona Stanley Hospital, Murdoch University & University of Notre Dame Australia.